The finding was confirmed by transfection of CD49d-negative tumor cells with CD49d carrying a point mutation prohibiting phosphorylation and FAK binding and by transfection of a CD44-negative tumor line with CD44 harboring a point mutation in the ezrin binding site, or with cytoplasmic tail-truncated CD44. Here, PTK2 is linked to neoplasm.